Home > Leadership Team

Leadership Team

Barry Fishman

Chief Executive Officer

Mr. Fishman has over 30 years of experience in the pharmaceutical industry and is the former CEO of Teva Canada. During his tenure at Teva Canada, Mr. Fishman executed a growth plan that resulted in a five-fold increase in revenue through acquisitions and organic growth. Mr. Fishman is also the past Chair of the Canadian Generic Manufacturers Association. Previously, as CEO of Taro Canada, Mr. Fishman tripled sales through organic growth and market expansion in the form of a new private label division and the establishment of a new branded dermatology business. He began his pharmaceutical career at Eli Lilly, where he advanced through several cross-functional leadership roles, including Vice President of Marketing.

Frank Rotmann

VP and Head of European Operations

Mr. Rotmann joined Merus Labs International in May 2015 as Vice President and Head of European Operations. He has over 20 years of experience in the pharmaceutical industry most recently as VP for Central Eastern Europe for Takeda Pharmaceuticals. Previously, Mr. Rotmann held both country and regional responsibilities with full P&L accountability and a strong record of transforming businesses to profitable growth. He has also held European and US-based leadership roles at Eli Lilly, Sanofi, Altana and Nycomed. Mr. Rotmann has a Master of Business and Engineering degree from the Karlsruhe Institute of Technology (KIT) in Germany.

Dr. Michael Bumby

Chief Financial Officer

Dr. Bumby was most recently the CFO of Acerus Pharmaceuticals Inc., a Canadian-based pharmaceutical company involved in R&D and product commercialization. Prior to that he was CFO for Antibe Therapeutics Inc., a Canadian-based biotech public where he took the company public through an IPO. Dr. Bumby had a diverse 14 year career at Eli Lilly, including Corporate Finance & Investment Banking at Lilly's global headquarters in Indianapolis leading international M&A and business development activities for early and late stage assets, and regional CFO for Lilly's Czech and Slovak subsidiaries based in Prague. He holds a Doctor of Veterinary Medicine from the University of Guelph and an MBA from the University of Toronto.

Geoff Morrow

VP, Business Development

Mr. Morrow leads all Business Development activities for International regions and Canada. Mr. Morrow has over 15 years of extensive International, US and Canadian Pharmaceutical experience in both commercial operations and business development arenas. He started his career with Astra Zeneca and held both marketing and sales leadership roles. Mr. Morrow has held roles with Astellas Canada as Director Corporate Planning and Business Development and Eli Lilly in several capacities including Marketing Team Leader and Global Marketing. In addition to his corporate experience, he has been on both industry advisory boards for Rx&D and the Canadian Urological Association. Mr. Morrow has a Bachelor's Degree from the University of Guelph in Business Management and Economics..

Frank Fokkinga

VP, Global Regulatory Affairs, Quality and Compliance

Mr. Fokkinga has over 30 years of pharmaceutical experience in regulatory affairs, global market research, business development and market access. Mr. Fokkinga has a proven history of success with gaining product approval and market access across Europe in a variety of therapeutic categories. Mr. Fokkinga previously served as Vice President, International Regulatory Affairs at Takeda Pharmaceuticals. He also progressed through a variety of leadership roles at Genzyme (now part of Sanofi) and Organon (now part of Merck).